secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001193125-22-298895
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios appoints Tsveta Milanova as CCO effective Jan 3, 2023; Richa Poddar departs Dec 31, 2022
--------------------------------------------------------------------------------

- Tsveta Milanova named Chief Commercial Officer, will succeed Richa Poddar effective Jan 3, 2023.
- Milanova previously SVP US Commercial at Alexion; brings rare disease commercial launch experience.
- Poddar will receive $450K severance plus 2022 target bonus and 12-month COBRA coverage.
- Milanova's base salary $510K, target bonus 45%, sign-on bonus $150K, plus equity grants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522298895/0001193125-22-298895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000119312522298895/d407010d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-298895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer